| Hypothesized role of pregnancy hormones on HER2+ breast tumor development. | |
| | |
MedLine Citation:
|
PMID: 23135573 Owner: NLM Status: Publisher |
Abstract/OtherAbstract:
|
Breast cancer incidence rates have declined among older but not younger women; the latter are more likely to be diagnosed with breast cancers carrying a poor prognosis. Epidemiological evidence supports an increase in breast cancer incidence following pregnancy with risk elevated as much as 10 years post-partum. We investigated the association between years since last full-term pregnancy at the time of diagnosis (≤10 or >10 years) and breast tumor subtype in a case series of premenopausal Hispanic women (n = 627). Participants were recruited in the United States, Mexico, and Spain. Cases with known estrogen receptor (ER), progesterone receptor (PR), and HER2 status, with one or more full-term pregnancies ≥1 year prior to diagnosis were eligible for this analysis. Cases were classified into three tumor subtypes according to hormone receptor (HR+ = ER+ and/or PR+; HR- = ER- and PR-) expression and HER2 status: HR+/HER2-, HER2+ (regardless of HR), and triple negative breast cancer. Case-only odds ratios (ORs) and 95 % confidence intervals (CIs) were calculated for HER2+ tumors in reference to HR+/HER2- tumors. Participants were pooled in a mixed-effects logistic regression model with years since pregnancy as a fixed effect and study site as a random effect. When compared to HR+/HER2- cases, women with HER2+ tumors were more likely be diagnosed in the post-partum period of ≤10 years (OR = 1.68; 95 % CI, 1.12-2.52). The effect was present across all source populations and independent of the HR status of the HER2+ tumor. Adjusting for age at diagnosis (≤45 or >45 years) did not materially alter our results (OR = 1.78; 95 % CI, 1.08-2.93). These findings support the novel hypothesis that factors associated with the post-partum breast, possibly hormonal, are involved in the development of HER2+ tumors. |
| | |
Authors:
|
Giovanna I Cruz; María Elena Martínez; Loki Natarajan; Betsy C Wertheim; Manuela Gago-Dominguez; Melissa Bondy; Adrian Daneri-Navarro; María Mercedes Meza-Montenegro; Luis Enrique Gutierrez-Millan; Abenaa Brewster; Pepper Schedin; Ian K Komenaka; J Esteban Castelao; Angel Carracedo; Carmen M Redondo; Patricia A Thompson |
Related Documents
:
|
3725013 - Ct findings in cerebral metastases. 7612003 - Progress on therapy of breast cancer with vitamin q10 and the regression of metastases. 21938273 - Squamous cell carcinoma - similarities and differences among anatomical sites. |
Publication Detail:
|
Type: JOURNAL ARTICLE Date: 2012-11-8 |
Journal Detail:
|
Title: Breast cancer research and treatment Volume: - ISSN: 1573-7217 ISO Abbreviation: Breast Cancer Res. Treat. Publication Date: 2012 Nov |
Date Detail:
|
Created Date: 2012-11-8 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 8111104 Medline TA: Breast Cancer Res Treat Country: - |
Other Details:
|
Languages: ENG Pagination: - Citation Subset: - |
Affiliation:
|
School of Public Health, University of California, Berkeley, Berkeley, CA, USA. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Validity of the proliferation markers Ki67, TOP2A, and RacGAP1 in molecular subgroups of breast canc...
Next Document: Tumor scatter after neoadjuvant therapy for rectal cancer: are we dealing with an invisible margin?